Free Trial

CalciMedica (CALC) Competitors

$4.23
+0.06 (+1.44%)
(As of 11:22 AM ET)

CALC vs. CARA, VCNX, GLSI, STTK, TRVI, VACC, PRLD, BMEA, XBIT, and RZLT

Should you be buying CalciMedica stock or one of its competitors? The main competitors of CalciMedica include Cara Therapeutics (CARA), Vaccinex (VCNX), Greenwich LifeSciences (GLSI), Shattuck Labs (STTK), Trevi Therapeutics (TRVI), Vaccitech (VACC), Prelude Therapeutics (PRLD), Biomea Fusion (BMEA), XBiotech (XBIT), and Rezolute (RZLT). These companies are all part of the "pharmaceutical preparations" industry.

CalciMedica vs.

CalciMedica (NASDAQ:CALC) and Cara Therapeutics (NASDAQ:CARA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, earnings, analyst recommendations, institutional ownership, profitability, valuation, media sentiment, dividends and risk.

CalciMedica currently has a consensus target price of $20.67, suggesting a potential upside of 392.06%. Cara Therapeutics has a consensus target price of $3.93, suggesting a potential upside of 1,033.53%. Given Cara Therapeutics' higher probable upside, analysts clearly believe Cara Therapeutics is more favorable than CalciMedica.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
CalciMedica
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
Cara Therapeutics
0 Sell rating(s)
6 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
2.00

44.7% of Cara Therapeutics shares are owned by institutional investors. 53.3% of CalciMedica shares are owned by insiders. Comparatively, 3.1% of Cara Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

CalciMedica has a beta of 1.28, suggesting that its share price is 28% more volatile than the S&P 500. Comparatively, Cara Therapeutics has a beta of 0.69, suggesting that its share price is 31% less volatile than the S&P 500.

In the previous week, CalciMedica and CalciMedica both had 1 articles in the media. CalciMedica's average media sentiment score of 0.22 beat Cara Therapeutics' score of 0.00 indicating that CalciMedica is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
CalciMedica
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Cara Therapeutics
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

CalciMedica has a net margin of 0.00% compared to Cara Therapeutics' net margin of -723.49%. CalciMedica's return on equity of -143.95% beat Cara Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
CalciMedicaN/A -143.95% -102.67%
Cara Therapeutics -723.49%-174.15%-105.26%

CalciMedica has higher earnings, but lower revenue than Cara Therapeutics. CalciMedica is trading at a lower price-to-earnings ratio than Cara Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
CalciMedicaN/AN/A-$34.36M-$2.15-1.97
Cara Therapeutics$20.97M0.90-$118.51M-$2.25-0.15

Cara Therapeutics received 655 more outperform votes than CalciMedica when rated by MarketBeat users. However, 92.31% of users gave CalciMedica an outperform vote while only 74.28% of users gave Cara Therapeutics an outperform vote.

CompanyUnderperformOutperform
CalciMedicaOutperform Votes
12
92.31%
Underperform Votes
1
7.69%
Cara TherapeuticsOutperform Votes
667
74.28%
Underperform Votes
231
25.72%

Summary

CalciMedica beats Cara Therapeutics on 11 of the 16 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CALC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

CALC vs. The Competition

MetricCalciMedicaPharmaceutical IndustryMedical SectorNASDAQ Exchange
Market Cap$45.47M$7.08B$5.21B$8.45B
Dividend YieldN/A2.67%2.79%3.95%
P/E Ratio-1.9710.23121.3615.07
Price / SalesN/A310.082,156.3482.72
Price / CashN/A32.7535.5534.86
Price / Book2.985.784.874.48
Net Income-$34.36M$147.01M$110.55M$215.94M
7 Day Performance-13.50%-1.63%-0.23%0.49%
1 Month Performance-16.07%6.98%7.33%5.91%
1 Year Performance17.20%-4.39%3.98%0.29%

CalciMedica Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
CARA
Cara Therapeutics
4.8078 of 5 stars
4.81 / 5 stars
$0.35
-3.6%
$3.93
+1,014.9%
-88.7%$19.29M$20.97M-0.1680Analyst Forecast
VCNX
Vaccinex
0 of 5 stars
0.00 / 5 stars
$6.57
-4.1%
N/A-88.1%$10.38M$570,000.00-0.0837Gap Up
GLSI
Greenwich LifeSciences
2.9832 of 5 stars
2.98 / 5 stars
$15.63
-1.0%
$36.00
+130.3%
+67.3%$201.31MN/A-21.713Positive News
STTK
Shattuck Labs
1.8633 of 5 stars
1.86 / 5 stars
$4.19
+3.5%
$11.00
+162.5%
+70.0%$199.24M$1.66M-2.1775Positive News
Gap Up
TRVI
Trevi Therapeutics
3.1537 of 5 stars
3.15 / 5 stars
$2.80
-0.4%
$8.00
+185.7%
+20.4%$197.20MN/A-8.2425Positive News
Gap Up
VACC
Vaccitech
0 of 5 stars
0.00 / 5 stars
$5.00
+11.4%
$7.63
+52.5%
-32.3%$192.74M$13.42M-3.5033Gap Up
PRLD
Prelude Therapeutics
0.1035 of 5 stars
0.10 / 5 stars
$4.56
+14.9%
$4.75
+4.2%
+13.1%$191.89MN/A-2.43128
BMEA
Biomea Fusion
3.4182 of 5 stars
3.42 / 5 stars
$5.29
+6.7%
$28.25
+434.0%
-76.6%$190.12MN/A-1.48110Gap Up
XBIT
XBiotech
0 of 5 stars
0.00 / 5 stars
$6.22
-6.6%
N/A+26.2%$189.46M$4.01M-6.1082Positive News
RZLT
Rezolute
2.855 of 5 stars
2.86 / 5 stars
$4.70
+9.8%
$9.67
+105.7%
+117.2%$188.63MN/A-4.1257Analyst Forecast
Positive News

Related Companies and Tools

This page (NASDAQ:CALC) was last updated on 7/19/2024 by MarketBeat.com Staff

From Our Partners